NLRP3 and colitis: Moreover, as the possible metabolite of compound 4, coumaric acid, when combined with other anti-inflammatory compounds, could enhance the inhibitory effect on IL-1β release by NLRP3, thereby enhancing the drug’s ability to facilitate recovery from DSS-induced colitis in mice [31].